Small Molecule Inhibitors of the Mitochondrial Permeability Transition Pore (PTP)
OHSU # 1967
Compositions for Treatment of Neurological and Oxidative Stress Disorders
Researchers at Oregon Health & Science University and Kansas University discovered novel small molecule inhibitors of mitochondrial permeability transition pore (mtPTP) for treatment of cellular disorders associated with an over-accumulation of mitochondrial calcium or reactive oxygen species. Compounds in this class are the most potent mtPTP inhibitors known and are useful for therapeutically challenging human diseases, such as, multiple sclerosis (MS), amyotropic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MDs), type II diabetes, heart infarction, and stroke.
Technology 1967 is available for exclusive licensing and/or collaborative co-development.
Patent Status: Provisional patent application filed.
If interested in learning more, please contact Travis Cook (email@example.com) and reference Tech Id No. 1967. OHSU Investigators: Dennis Bourdette, MD; Michael Forte, Ph.D.
- Michael Forte, VI.Vollum Institute
- Dennis Bourdette, SM.Neurology
- Paolo Bernardi
- Justina Sileikyte, VI.Vollum Institute
- Frank Schoenen
- Sudeshna Roy
For more information, contact:
Senior Technology Development Manager